Latest Press Release on flu vaccine

Military Study Shows Prevention of Novel A/H1N1 Virus Infection is Vaccine-Type and Age-Dependent
WASHINGTON, Nov. 19 /PRNewswire/ -- Immunization with either live attenuated influenza vaccine (LAIV, also known as FluMist®), or trivalent inactivated influenza vaccine (TIV), appears to offer a protection (~ 45%) against the novel A/H1N1 virus, the cause of the present influenza ...

---

National Patient Safety Foundation Supports Mandatory Flu Vaccinations for Healthcare Workers
BOSTON, Nov. 18 /PRNewswire/ -- The National Patient Safety Foundation (NPSF) today issued the following position statement supporting mandatory influenza vaccination of health care workers: The National Patient Safety Foundation recognizes vaccine-preventab...

---

Macomb County Health Department Schedules Communitywide H1N1 Flu Vaccine Clinic Nov. 24
MT. CLEMENS, Mich., Nov. 18 /PRNewswire/ -- A communitywide H1N1 vaccine clinic has been scheduled for next Tuesday, Nov. 24, the Macomb County Health Department announced today. It is being offered at no charge. The clinic will be held from noon to 7 p.m. at Freedom Hill...

---

Will Vaccines Change the Face of Cancer Treatment?
NEW YORK, NY -- 11/24/09 -- The H1N1 vaccine has spurred media interest in vaccines, as well as predictions of vaccines for a host of new diseases. According to Kalorama Information, certain cancers may be added to the list of diseases for which va..

---

Pennsylvania Department of Health Begins Statewide H1N1 Vaccination Clinics Targeting Priority Populations; Some Appointments Still Available
HARRISBURG, Pa., Nov. 20 /PRNewswire-USNewswire/ -- The Department of Health today began providing free H1N1 flu shots to members of priority groups that did not have previous access to the vaccine. A total of 18 clinics are being held statewide on Nov. 20-22. Friday's clinic...

---

AFFiRiS AG: Interim Analysis of Clinical Phase I Data Triggered Decision to Move Alzheimer's Vaccine Candidate AD02 into Clinical Phase II Testing
VIENNA, Austria, November 19 /PRNewswire/ -- AFFiRiS AG will focus its Alzheimer's vaccine program on one product candidate at an unexpectedly early stage of development: the vaccine candidate AD02 is planned to enter into Phase II clinical trial early in...

---

Immunovaccine Licenses Vaccine Platform to Pfizer Animal Health
HALIFAX, NOVA SCOTIA -- 11/23/09 -- Immunovaccine Inc. (TSX VENTURE: IMV), a vaccine development company, today announced the signing of an exclusive, worldwide license agreement with Pfizer Animal Health for Immunovaccine's patented vaccine delive..

---

Genocea Biosciences Expands Scientific Advisory Board with Appointment of Four Vaccine Experts
CAMBRIDGE, Mass. - Genocea Biosciences, a vaccine discovery and development company, today announced the appointments of David Bernstein, M.D., M.A., of the Cincinnati Children’s Hospital; Robert Coffman, Ph.D., of Dynavax Technologies; Patrice Dubois, Ph.D., of the University of Lausa

---

Inovio Biomedical Universal Flu Vaccines Demonstrate Broadly Protective Immune Responses Against Multiple Seasonal & Pandemic Influenza Viruses in Pre-Clinical Studies
SAN DIEGO - Inovio Biomedical Corporation (NYSE Amex:INO), a leader in DNA vaccine design, development and delivery, announced today that a combination of its synthetic consensus H1N1, H2N2, H3N2, and H5N1 influenza vaccine candidates achieved protective antibody responses against several

---

Inovio Biomedical Universal DNA Vaccine for Chikungunya Virus Demonstrates Protective Antibody Responses in Monkey Model
SAN DIEGO - Inovio Biomedical Corporation (NYSE Amex: INO), a leader in DNA vaccine design, development and delivery, announced today that the company's SynCon™ Chikungunya virus DNA vaccine induced protective neutralizing antibody responses in a preclinical non-human primate model. Dr

---

GAVI’s Impact on Vaccine Market is Bringing Down Prices
HANOI, Vietnam - Following the increasing impact of the GAVI Alliance on the vaccine market, the price of one of the major combination vaccines, the pentavalent, is falling considerably, enabling GAVI’s partners to vaccinate millions of more children in the developing world.

---